• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Apixaban for Anticoagulation after Robotic Mitral Valve Repair
CONCLUSIONS: Anticoagulation with apixaban after minimally invasive robotic MVRep is safe and has similar rates of bleeding and thromboembolism compared to patients treated with warfarin.PMID:35973484 | DOI:10.1016/j.athoracsur.2022.07.045
Source: The Annals of Thoracic Surgery - August 16, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Piotr K Mazur Arman Arghami Shea A Macielak Scott D Nei Jason K Viehman Katherine S King Richard C Daly Juan A Crestanello Hartzell V Schaff Joseph A Dearani Source Type: research

Evaluation of Prescribing Practices and Outcomes Using Direct-Acting Oral Anticoagulants After Cardiac Surgery
Clin Ther. 2021 May 30:S0149-2918(21)00203-4. doi: 10.1016/j.clinthera.2021.04.009. Online ahead of print.ABSTRACTPURPOSE: Cardiac surgery patients frequently require anticoagulation. Warfarin remains the preferred agent, and a few trials have reported negative outcomes with the use of direct-acting oral anticoagulants (DOACs) in these patients. Therefore, limited literature exists that supports the dosing, safety, and efficacy of DOACs within the cardiac surgery population.METHODS: This single-center, retrospective analysis was conducted at a tertiary academic medical center. All data were extrapolated from electronic med...
Source: Clinical Therapeutics - June 3, 2021 Category: Drugs & Pharmacology Authors: Dareen M Kanaan Bryan M Cook Julie Kelly Rhynn Malloy Source Type: research

Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience
Semin Thromb Hemost DOI: 10.1055/s-0037-1615261This is an observational study to investigate the efficacy and safety of nonvitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) patients with bioprosthetic valves or prior surgical valve repair in clinical practice. A total of 122 patients (mean age: 74.1 ± 13.2; 54 females) with bioprosthetic heart valve or surgical valve repair and AF treated with NOACs were included in the analysis. The mean CHA2DS2-VASc (Congestive heart failure, Hypertension, Age >75 years, Diabetes mellitus, prior Stroke or transient ischemic attack, Vascular disease) and...
Source: Seminars in Thrombosis and Hemostasis - January 5, 2018 Category: Hematology Authors: Russo, Vincenzo Attena, Emilio Mazzone, Carmine Esposito, Francesca Parisi, Valentina Bancone, Ciro Rago, Anna Nigro, Gerardo Sangiuolo, Raffaele D' Onofrio, Antonio Tags: Original Article Source Type: research

Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis
Conclusions Rivaroxaban is a valuable treatment option for patients with biological prostheses, repaired mitral valves, or a tubular aortic graft in order to prevent thromboembolic complications.
Source: Clinical Drug Investigation - July 10, 2016 Category: Drugs & Pharmacology Source Type: research

How to define valvular atrial fibrillation?
Abstract Atrial fibrillation (AF) confers a substantial risk of stroke. Recent trials comparing vitamin K antagonists (VKAs) with non-vitamin K antagonist oral anticoagulants (NOACs) in AF were performed among patients with so-called "non-valvular" AF. The distinction between "valvular" and "non-valvular" AF remains a matter of debate. Currently, "valvular AF" refers to patients with mitral stenosis or artificial heart valves (and valve repair in North American guidelines only), and should be treated with VKAs. Valvular heart diseases, such as mitral regurgitation, aortic stenosis (AS) and aortic insufficiency, do...
Source: Archives of Cardiovascular Diseases - July 13, 2015 Category: Cardiology Authors: Fauchier L, Philippart R, Clementy N, Bourguignon T, Angoulvant D, Ivanes F, Babuty D, Bernard A Tags: Arch Cardiovasc Dis Source Type: research

Long-Term Outcomes of the Maze Procedure Combined With Mitral Valve Repair: Risk of Thromboembolism Without Anticoagulation Therapy.
CONCLUSIONS: Adopting appropriate selection criteria for discontinuing anticoagulation therapy, the majority of patients receiving concomitant mitral repair and the Maze procedure can discontinue warfarin with excellent long-term safety profiles. PMID: 26116476 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - June 23, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Hwang SK, Yoo JS, Kim JB, Jung SH, Choo SJ, Chung CH, Lee JW Tags: Ann Thorac Surg Source Type: research

Long-Term Outcomes of the Maze Procedure Combined With Mitral Valve Repair: Risk of Thromboembolism Without Anticoagulation Therapy
Conclusions Adopting appropriate selection criteria for discontinuing anticoagulation therapy, the majority of patients receiving concomitant mitral repair and the Maze procedure can discontinue warfarin with excellent long-term safety profiles.
Source: The Annals of Thoracic Surgery - June 23, 2015 Category: Cardiovascular & Thoracic Surgery Source Type: research

Postoperative warfarin following mitral valve repair or bioprosthetic valve replacement.
CONCLUSION: The use of postoperative warfarin following MVR does not reduce the incidence of stroke at early follow up. However, there remains a trend for improved long-term outcomes in those patients receiving postoperative warfarin therapy. PMID: 24383387 [PubMed - indexed for MEDLINE]
Source: Journal of Heart Valve Disease - December 1, 2014 Category: Cardiology Tags: J Heart Valve Dis Source Type: research

Preoperative risk factor analysis of postoperative stroke after Cox-maze procedure with mitral valve repair
Conclusions: In the group of patients who underwent the Cox-Maze procedure with mitral valve repair, having a stroke history was the only preoperative risk factor that could lead to a stroke event after surgery. Accordingly, patients with affliction of ischemic stroke, albeit sustained sinus rhythm, may require prophylactic anticoagulation.
Source: BMC Cardiovascular Disorders - September 11, 2014 Category: Cardiology Authors: Jun Seok KimSong Am LeeJae Bum ParkHyun Keun CheeJin Woo Chung Source Type: research

Mitral valve repair and bioprosthetic replacement without postoperative anticoagulation does not increase the risk of stroke or mortality ADULT CARDIAC
CONCLUSIONS Despite current guidelines recommending postoperative anticoagulation following MVRR or bioprosthetic replacement, the avoidance of warfarin does not increase perioperative complications and has no impact on intermediate survival. Accordingly, a prospective randomized study to adjudicate the role of extended warfarin thromboprophylaxis in mitral valve surgery is warranted.
Source: European Journal of Cardio-Thoracic Surgery - June 13, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Schwann, T. A., Engoren, M., Bonnell, M., Clancy, C., Khouri, S., Kabour, A., Jamil, T., Habib, R. H. Tags: ADULT CARDIAC Source Type: research

Psychiatric remission with warfarin: Should psychosis be addressed as plasminogen activator imbalance?
Conclusion: Our findings suggest that normalization of plasminogen activator levels in the brain may induce long-term remission of psychotic symptoms. Randomized controlled studies may help clarify the role of anticoagulation in the treatment of psychosis.
Source: Medical Hypotheses - December 3, 2012 Category: Biomedical Science Authors: Silvia Hoirisch-Clapauch, Antonio E. Nardi Tags: Articles Source Type: research